These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 26703343)
21. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739 [TBL] [Abstract][Full Text] [Related]
22. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum. Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117 [TBL] [Abstract][Full Text] [Related]
23. [Effects of mucolytic agents and macrolides in the treatment of COPD]. Yamaya M Nihon Rinsho; 2016 May; 74(5):833-8. PubMed ID: 27254955 [TBL] [Abstract][Full Text] [Related]
24. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Rojas-Reyes MX; García Morales OM; Dennis RJ; Karner C Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008532. PubMed ID: 27271056 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Miravitlles M; D'Urzo A; Singh D; Koblizek V Respir Res; 2016 Sep; 17(1):112. PubMed ID: 27613392 [TBL] [Abstract][Full Text] [Related]
27. Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β Ferroni E; Belleudi V; Cascini S; Di Martino M; Kirchmayer U; Pistelli R; Patorno E; Formoso G; Fusco D; Perucci CA; Davoli M; Agabiti N; J Clin Pharmacol; 2016 Nov; 56(11):1423-1432. PubMed ID: 27095425 [TBL] [Abstract][Full Text] [Related]
28. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Poole P; Sathananthan K; Fortescue R Cochrane Database Syst Rev; 2019 May; 5(5):CD001287. PubMed ID: 31107966 [TBL] [Abstract][Full Text] [Related]
29. Inhaled corticosteroids in children with persistent asthma: effects on growth. Zhang L; Prietsch SO; Ducharme FM Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026 [TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Sobieraj DM; White CM; Coleman CI Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985 [TBL] [Abstract][Full Text] [Related]
32. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Poole PJ; Black PN Am J Respir Med; 2003; 2(5):367-70. PubMed ID: 14719989 [TBL] [Abstract][Full Text] [Related]
33. [Mucolytic and antioxidant agents for exacerbations of chronic obstructive pulmonary disease: A meta-analysis]. Li X; Sun H; Liu C; Kang J Zhonghua Jie He He Hu Xi Za Zhi; 2015 Aug; 38(8):600-6. PubMed ID: 26703343 [TBL] [Abstract][Full Text] [Related]